Jose J G Marin, Rocio I R Macias, Maitane Asensio, Marta R Romero, Alvaro G Temprano, Olívia R Pereira, Silvia Jimenez, Jose Luis Mauriz, Silvia Di Giacomo, Matias A Avila, Thomas Efferth, Oscar Briz
In contrast to other types of cancers, there is no available efficient pharmacological treatment to improve the outcomes of patients suffering from major primary liver cancers, i.e., hepatocellular carcinoma and cholangiocarcinoma. This dismal situation is partly due to the existence in these tumors of many different and synergistic mechanisms of resistance, accounting for the lack of response of these patients, not only to classical chemotherapy but also to more modern pharmacological agents based on the inhibition of tyrosine kinase receptors (TKIs) and the stimulation of the immune response against the tumor using immune checkpoint inhibitors (ICIs)...
May 6, 2024: American Journal of Physiology. Cell Physiology